ubmslateOT-logo-ubm

OT mobile menu

Topics:

Home

Atezolizumab Reduced Tumor Size in Patients With Advanced Bladder Cancer

Good news to share during Bladder Cancer Awareness Month. Image © Sebastian Kaulitzki/ Shutterstock.com.

 

Image © Anita Ponne/ Shutterstock.com.
Image © Anita Ponne/ Shutterstock.com.
Image © Anita Ponne/ Shutterstock.com.
Image © Blamb / Shutterstock.com.
Image © Blamb / Shutterstock.com.
Image © Blamb / Shutterstock.com.
Nivolumab showed greater overall survival in patients with metastatic squamous NSCLC, - See more at: http://www.oncotherapynetwork.com/asco-2015/nivolumab-improves-response-...

Recent Content

A 20-year-old young man presents with hypertension and a left kidney mass. After further evaluation, a biopsy is performed. What is your diagnosis?

Oncologists now have a new tool for treating locally advanced basal cell carcinoma. On July 24, 2015, The US Food and Drug Administration (FDA) approved sonidegib (Odomzo) to treat patients with this type of cancer after it has recurred following surgery or radiation therapy.

For the first time, researchers have found that a checkpoint inhibitor may result in a survival advantage in advanced renal cell carcinoma (RCC), according to new data from an open-label, randomized, phase III study.

A new study finds an aggressive form of lymphoma responds to ibrutinib (Imbruvica), which targets the B-cell receptor. This was first reported in the July 20, 2015 online edition of Nature Medicine.

A 75-year-old male patient develops painful erythema around his nails 10 weeks after starting cancer treatment. Which medication is most likely responsible?

Blinatumomab (Blincyto) may induce complete remission within 2 cycles of treatment in adults with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia (ALL), according to a new phase II open-label, single-arm, multicenter trial.

A simple protein may be able to slow the growth or stop breast cancer growth altogether, according to a new study.

By clicking Accept, you agree to become a member of the UBM Medica Community.